Robatumumab Biosimilar - Research Grade

Human

IGF1R

>1mg/ml

Human IgG1 (E356D/M358L)-kappa

Teprotumumab Biosimilar - Research Grade (ICH5128), Cixutumumab Biosimilar - Research Grade (ICH5144), Figitumumab Biosimilar - Research Grade (ICH5154), Ganitumab Biosimilar - Research Grade (ICH5216), Dalotuzumab Biosimilar - Research Grade (ICH5463), Lonigutamab Biosimilar - Research Grade (ICH5656), Veligrotug Biosimilar - Research Grade (ICH5972)

https://www.imgt.org/mAb-DB/

ICH3002

P06213;P08069

Blue ice

This product is an unconjugated, non-therapeutic recombinant analog of robatumumab (SCH 717454), a fully human anti-IGF1R monoclonal antibody, supplied for research use only. It is built around the IGF1R target and reproduces the antigen-binding specificity of the originator, formatted as a human IgG1-kappa (with the E356D/M358L allotype substitutions noted on the card). It is not the clinical drug and is not intended for human or veterinary use. The biosimilar is useful as a defined, reproducible reagent for in-vitro and preclinical studies: as a positive control or benchmark in IGF1R binding and blocking assays, for probing IGF1R-driven signaling and receptor down-modulation, for ADCC-format and antibody-engineering workflows, and as a comparator when characterizing novel anti-IGF1R candidates. It is available at research grade with low endotoxin (<1 EU/mg; ultra-low <0.5 EU/mg options), and in bulk milligram-to-gram quantities suitable for in-vitro standards and larger preclinical experiments. Lot-to-lot consistency supports use as an assay reference standard across cell-based and biochemical experiments. IGF1R (type 1 insulin-like growth factor receptor; UniProt P08069) is a receptor tyrosine kinase expressed as a disulfide-linked alpha2-beta2 heterotetramer. The extracellular alpha subunits bind IGF-1 and, with lower affinity, IGF-2; ligand binding activates the intracellular beta-subunit kinase domains, driving autophosphorylation and recruitment of IRS-1/2 and Shc. This propagates PI3K-AKT and RAS-MAPK signaling, promoting cell proliferation, survival, growth, and transformation. IGF1R shares high homology with the insulin receptor (INSR) and can form IGF1R-INSR hybrid receptors, a point relevant to specificity characterization. Because IGF1R signaling supports tumor cell growth and resistance to apoptosis, and is overexpressed in several cancers, it has been widely studied as an oncology target; anti-IGF1R antibodies act by blocking ligand engagement and inducing receptor internalization and degradation.

IR, Insulin-like growth factor I receptor, IGF-I receptor, Insulin receptor, Insulin-like growth factor 1 receptor, INSR

Detects human IGF1R

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

Q: Is the Robatumumab biosimilar available in gram quantities?

A: Yes — it is supplied in scalable milligram to gram quantities for heavy-usage and high-throughput laboratories.

Q: Is this research-grade Robatumumab biosimilar suitable for in vivo studies?

A: Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Robatumumab biosimilar target?

A: It is an unconjugated, non-therapeutic analog of Robatumumab that binds human IGF1R.